AstraZeneca's IMFINZI plus enfortumab vedotin reduced disease progression/recurrence risk by 49% and mortality by 42% in muscle-invasive bladder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results